Literatur
- 1
Bilezikian J P, Potts J T, Fuleihan G el-H, Kleerekoper M, Neer R, Peacock M, Rastad J,
Silverberg S J, Udelsman R, Wells S A.
Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective
for the 21st century.
J Clin Endocrinol Metab.
2002;
87
5353-5361
- 2
Cohen D, Adachi J D.
The treatment of glucocorticoid-induced osteoporosis.
J Steroid Biochem Mol Biol.
2004;
88
337-349
- 3
Cohen S, Levy R M, Keller M, Boling E, Emkey R D, Greenwald M, Zizic T M, Wallach S,
Sewell K L, Lukert B P, Axelrod D W, Chines A A.
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter,
randomized, double-blind, placebo-controlled, parallel-group study.
Arthritis Rheum.
1999;
42
2309-2318
- 4
Cummings S R, Nevitt M C, Browner W S, Stone K, Fox K M, Ensrud K B, Cauley J, Black D,
Vogt T M.
Risk factors for hip fracture in white women. Study of osteoporotic fractures research
group.
N Engl J Med.
1995;
332
814-815
- 5
Kann P, Jocham A, Beyer J.
Hypothyreose, Hyperthyreose und Therapie mit Schilddrüsenhormonen: Einflüsse auf das
Skelettsystem.
Dtsch Med Wochenschr.
1997;
122
1392-1397
- 6
Kann P, Laudes M, Piepkorn B, Heintz A, Beyer J.
Suppressed levels of serum cortisol following high-dose oral dexamethasone administration
differ between healthy postmenopausal females and patients with established primary
vertebral osteoporosis.
Clin Rheumatol.
2001;
20
25-29
- 7
Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W, Beyer J.
Effect of long-term treatment with GH on bone metabolism, bone mineral density and
bone elasticity in GH-deficient adults.
Clin Endocrinol.
1998;
48
561-568
- 8
Kann P H.
Endosonographic imaging of the adrenals.
Endoscopy.
2005;
in press
- 9
Kann P H.
Growth hormone in anti-aging medicine: a critical review.
Aging Male.
2003;
6
257-263
- 10
Kann P H.
Wachstumshormon, Knochenstoffwechsel und Osteoporose beim Erwachsenen.
Dtsch Med Wochenschr.
2004;
129
1390-1394
- 11
Khosla S, Melton L J, Wermers R A, Crowson C S, O’Fallon W, Riggs B.
Primary hyperparathyroidism and the risk of fracture: a population-based study.
J Bone Miner Res.
1999;
14
1700-1707
- 12
Neer R M, Arnaud C D, Zanchetta J R, Prince R, Gaich G A, Reginster J Y, Hodsman A B,
Eriksen E F, Ish-Shalom S, Genant H K, Wang O, Mitlak B H.
Effect of parathyroid hormone (1 - 34) on fractures and bone mineral density in postmenopausal
women with osteoporosis.
N Engl J Med.
2001;
344
1434-1441
- 13
Oertel H, Strasburger C J, Kann P, Quabbe H J.
Empfehlungen zur Indikation und Durchführung einer Wachstumshormon-Substitution im
Erwachsenenalter.
Dtsch Med Wochenschr.
1998;
123
883-886
- 14
Olszynski W P, Shawn Davison K, Adachi J D, Brown J P, Cummings S R, Hanley D A, Harris S P,
Hodsman A B, Kendler D, McClung M R, Miller P D, Yuen C K.
Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment.
Clin Ther.
2004;
26
15-28
- 15
Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R,
Pietschmann P, Vandormael K, Lombardi A.
Alendronate for the treatment of osteoporosis in men.
N Engl J Med.
2000;
343
604-610
- 16
Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson B A.
Reduced bone mineral content in adult patients with growth hormone deficiency.
Acta Endocrinol.
1993;
129
201-206
- 17
Snyder P J, Peachey H, Hannoush P, Berlin J A, Loh L, Holmes J H, Dlewati A, Staley J,
Santanna J, Kapoor S C, Attie M F, Haddad J G, Strom B L.
Effect of testosterone treatment on bone mineral density in men over 65 years of age.
J Clin Endocrinol Metab.
1999;
84
1966-1972
- 18
Strasburger C J, Schopohl J, Kann P, Oertel H.
Diagnostische Kriterien für die Indikation zur Wachstumshormonsubstitution bei Erwachsenen.
Dtsch Med Wochenschr.
1997;
122
861-863
- 19
Uzzan B, Campos J, Cucherat M, Nony P, Boissel J P, Perret G Y.
Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.
J Clin Endocrinol Metab.
1996;
81
4278-4289
- 20
Vestergaard P, Mosekilde L.
Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up
study in 16,249 patients.
Thyroid.
2002;
12
411-419
- 21
Vestergaard P, Mosekilde L.
Fractures in patients with primary hyperparathyroidism: nationwide follow-up study
of 1201 patients.
World J Surg.
2003;
27
343-349
- 22
Wallach S, Cohen S, Reid D M, Hughes R A, Hosking D J, Laan R F, Doherty S M, Maricic M,
Rosen C, Brown J, Barton I, Chines A A.
Effects of risedronate treatment on bone density and vertebral fracture in patients
on corticosteroid therapy.
Calcif Tissue Int.
2000;
67
277-285
- 23
Wejda B, Hintze G, Katschinski B, Olbricht T, Benker G.
Hip fractures and the thyroid: a case-control study.
J Intern Med.
1995;
237
241-247
- 24
Wilhelm B, Kann P.
Wachstumshormon und Knochen: Einfluss einer siebenjährigen Wachstumshormonsubstitution
auf Knochenstoffwechsel und Knochendichte bei Erwachsenen mit einem Wachstumshormonmangel.
Med Klin.
2004;
99
569-577
- 25
Wilson R J, Rao S, Ellis B, Kleerekoper M, Parfitt A M.
Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures.
Ann Intern Med.
1988;
109
959-962
- 26
Wüster C, Abs R, Bengtsson B A, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E,
Monson J P, Westberg B, Wilton P. KIMS Study Group and the KIMS International Board
.
Pharmacia & Upjohn International Metabolic Database. The influence of growth hormone
deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism
on fracture rate and bone mineral density.
J Bone Miner Res.
2001;
16
398-405
Prof. Dr. med. Peter Herbert Kann
Endokrinologie & Diabetologie, Klinikum der Philipps-Universität Marburg
35033 Marburg
Phone: 06421/2863135
Fax: 06421/2862733
Email: kannp@med.uni-marburg.de
